Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · lung-landscapes@6

SRR4296106

— · cohortSQ1

04c24cbd-5707-54ce-97ab-c9133719b306

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
cohortSQ1
subtype
cohortSQ1
age_years
58

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • E2F_TARGETS+0.600
  • G2M_CHECKPOINT+0.550
  • MTORC1_SIGNALING+0.490
  • MYC_TARGETS_V1+0.490
  • GLYCOLYSIS+0.480
  • OXIDATIVE_PHOSPHORYLATION+0.430
  • MYC_TARGETS_V2+0.410
  • DNA_REPAIR+0.330
  • CHOLESTEROL_HOMEOSTASIS+0.310
  • MITOTIC_SPINDLE+0.310

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.660
  • INTERFERON_GAMMA_RESPONSE-0.530
  • ALLOGRAFT_REJECTION-0.460
  • INFLAMMATORY_RESPONSE-0.440
  • IL6_JAK_STAT3_SIGNALING-0.420
  • COMPLEMENT-0.350
  • KRAS_SIGNALING_UP-0.340
  • TNFA_SIGNALING_VIA_NFKB-0.340
  • IL2_STAT5_SIGNALING-0.320
  • COAGULATION-0.250

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-77-6845-01A-11R-1949-07
lung-landscapes@6
—cohortSQ20.929
2TCGA-DQ-7588-01A-11R-2081-07
head-neck@1
——0.915
3BS_MV6ASWV9
brain-umap@2
ATRT—0.912
4MDT-AP-2956
medullo-epn-umap@date-based
MedMedulloblastoma0.909
5TCGA-94-A5I6-01A-21R-A27Q-07
lung-landscapes@6
—cohortSQ20.902
6TCGA-21-1075-01A-01R-0692-07
lung-landscapes@6
—cohortSQ20.901
7SRR8518327
breast-umap@18
—E0.899
8TCGA-BT-A20N-01A-11R-A14Y-07
bladder-landscape@3
——0.898
9MNG1011
mng-umap@100
——0.894
10TCGA-33-A4WN-01A-11R-A262-07
lung-landscapes@6
—cohortSQ20.889

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 26 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
E2F_TARGETS0.600Inavolisib— uncovered
G2M_CHECKPOINT0.550Inavolisib— uncovered
MTORC1_SIGNALING0.490Inavolisib— uncovered
MYC_TARGETS_V10.490Inavolisib— uncovered
GLYCOLYSIS0.480Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.430Remibrutinib— uncovered
MYC_TARGETS_V20.410Idelalisib— uncovered
DNA_REPAIR0.330Idelalisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.310Remibrutinib— uncovered
MITOTIC_SPINDLE0.310Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.290Idelalisib— uncovered
SPERMATOGENESIS0.270Inavolisib— uncovered
HYPOXIA0.240Idelalisib— uncovered
PEROXISOME0.240Idelalisib— uncovered
FATTY_ACID_METABOLISM0.230Inavolisib— uncovered
PROTEIN_SECRETION0.140Remibrutinib— uncovered
ESTROGEN_RESPONSE_LATE0.100Idelalisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.090Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.090Inavolisib— uncovered
UV_RESPONSE_UP0.090Idelalisib— uncovered